clinical investigation of the mistent drug eluting stent (des) in coronary artery disease

Conditions: Coronary Artery Disease

Summary: the dessolve ii clinical trial is to assess the safety and performance of the sirolimus-eluting mistent for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions in the native coronary arteries.

the dessolve ii clinical trial is to assess the safety and performance of the sirolimus-eluting mistent as compared to the endeavor des for the treatment for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo lesions in the native coronary arteries.

Eligibility criteria:
inclusion criteria: 1. age ≥18 and ≤85 years; 2. stable/unstable angina pectoris (class i-iv), documented ischemia/silent ischemia; 3. planned single, de novo, types a, b1 or b2 coronary lesions; 4. target lesion located in a native coronary artery; 5. target lesion in vessel ranging from 2.5 to 3.5 mm amenable to treatment (coverage) with a 30 mm long stent; 6. target lesion with \>50% diameter stenosis; 7. recent q-wave (\>72 hours) or non-q-wave myocardial infarction; 8. patients eligible for pci; 9. candidate for cabg ; 10. a patient may have one additional critical non-target lesion. 11. patient capable of providing informed consent and is willing to comply with all study requirements. exclusion criteria: 1. female patients of childbearing potential who do not have a confirmed negative pregnancy test at baseline and are not on some form of birth control; 2. recent q-wave mi \< 72 hours prior to the index procedure. 3. recent q- or non-q-wave mi with still elevated levels of cardiac markers (e.g. ck; and ck-mb if the ck is elevated); 4. lvef \<30% (within the previous 6-months); 5. patients in cardiogenic shock; 6. cva or tia within the past 6 months; 7. active gi bleeding within past 3 months; 8. any prior anaphylactic reaction to contrast agents; 9. chemotherapy within 30-days before or after the index procedure; 10. receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease; 11. renal dysfunction (creatinine \> 2.0 mg/dl or 177 µmol/l); 12. platelet count \ 700,000 cells/mm³; 13. white blood cell count \<3,000 cells/mm3; 14. hepatic disease; 15. heart transplant recipient; 16. known contraindication to dapt; 17. known hypersensitivity to sirolimus, cobalt-chromium, or to medications such as aspirin, heparin and angiomax (bivalirudin), and all three of the following: clopidogrel bisulfate (plavix), ticlopidine (ticlid), and prasugrel (effient); 18. life expectancy less than 12 months; 19. any major medical condition that may interfere with participation in this study; 20. patient is currently participating in an investigational drug or another device study and has not completed the follow-up to the primary endpoint, or the patient is planning on participating prior to completing 12-months follow-up; 21. target vessel has been treated within 10 mm proximal or distal to target lesion with any type of pci or within a year prior to index procedure; 22. planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter prior to stent placement; 23. patient previously treated at any time with brachytherapy; 24. planned coronary angioplasty or cabg in the first 9 months after the index procedure or any other planned intervention within 30-days post index procedure; 25. prior pci of a non-target vessel must be at least 14 days prior to study enrollment; 26. the intent to direct stent the target lesion; 27. angiographic exclusion criteria: * in-stent restenotic target lesion; * in-stent restenotic target lesion; * more than one lesion requiring treatment in the target vessel); * target vessel diameter \ 3.5 mm; * long target lesion not amenable to treatment with up to a 30 mm long stent; * left main critical disease (≥50% ds); * target lesion is located in a surgical bypass graft; * total target vessel occlusion (timi flow grade 0-1); * target lesion ostial location; * target lesion at bifurcation involving side branch \>2.5 mm or lateral branch that also requires stenting; * calcified target lesion that anticipates unsuccessful/impracticable predilation; * target vessel with excessive tortuosity or proximal angulation; * thrombus present in target vessel; * more than one non-target critical lesion; * non-target lesion to be treated during the index procedure meets any of the following criteria: 1. located within the target vessel; 2. located within a bypass graft ; 3. left main location; 4. chronic total occlusion 5. involves a complex bifurcation.

Keywords: coronary artery disease drug-eluting stent sirolimus